Allianz Asset Management Gmb H Cerevel Therapeutics Holdings, Inc. Transaction History

Allianz Asset Management Gmb H

  • $69.7 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$38.96 - $42.75 $3.48 Million - $3.82 Million
-89,400 Reduced 61.91%
55,000 $2.25 Million
Q4 2023

Feb 12, 2024
BUY
$20.27 - $42.44 $2.93 Million - $6.13 Million
144,400 New
144,400 $6.12 Million
Q2 2022

Aug 12, 2022
BUY
$20.62 - $37.15 $48,663 - $87,674
2,360 Added 9.13%
28,220 $746,000
Q1 2022

May 13, 2022
BUY
$23.5 - $35.38 $131,600 - $198,128
5,600 Added 27.64%
25,860 $905,000
Q4 2021

Feb 11, 2022
BUY
$29.21 - $44.64 $591,794 - $904,406
20,260 New
20,260 $657,000

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email